Cannabix Technologies Inc (OTCMKTS: BLOZF) is an exciting cannabis Company that is in the right place at the right time.
Last week Cannabix announced early testing with its breath collection unit (“BCU”) has thus far provided stable and consistent results. In late January, the Company received an initial version of its portable handheld device for the collection of breath samples at the point of care. Testing with human subjects using the BCU, has improved consistency of breath sample collection, and has provided important real-time data parameters on breath flow rate, volume, relative humidity, carbon dioxide levels, and temperature. Engineers may make additional adjustments to the BCU based on this early testing of the unit and additional units are planned to be built for field testing purposes.
The Company also reports recent characterization work with the Cannabix’s FAIMS (field asymmetric waveform ion mobility spectrometry) THC detection device has shown the ability to suppress a range of ions (both low mass and high mass) from the spectrum allowing for THC (∆9-tetrahydrocannabinol) detection from both human breath and standards. In particular, scientists are working quickly to finalize specific FAIMS geometries that will allow for optimal ion filtering capability. FAIMS works as an “ion blocking” technology, essentially blocking unwanted ions/analytes and allowing specified ions (like THC) to pass through for detection.
In addition to THC, Cannabix scientists are using FAIMS to detect two key metabolites of THC, being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards and in breath.
Cannabix Technologies Inc. (CSE: BLO, US OTC: BLOZF, Frankfurt: 8CT:FRA) is a Vancouver, B.C. based technology company and the developer of a Patent Pending Cannabis Drug Detection Device. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions.
Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.
To Find out the inside Scoop on Cannabix Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Earlier this year Cannabix said it has filed a Patent Cooperation Treaty (“PCT”) application titled, “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS” (PCT/CA2017/000042). This PCT covers intellectual property related to earlier versions of the Cannabix Marijuana Breathalyzer. Under its relationship with the University of Florida (“the University”), the Company has entered into a second license agreement with the University for PCT application CA2017/000042. The agreement provides Cannabix exclusive worldwide rights in the area of breath analysis of controlled substances. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of 9-tetrahydrocannabinol in human breath.
Cannabix engineers have improved on the design of the ionization source for the instrument which now allows for greater voltage control and precision, leading to greater signal and sensitivity. Furthermore, improvements have been made to the instrument’s heat control module. The Company’s patent portfolio includes an exclusive worldwide license of University of Florida (“UF”) US Patent 8,237,118 in the area of breath analysis of controlled substances. Additionally, the Company has licensed patent pending technology from UF (PCT/CA2017/000042), and has made its own patent applications since 2015. The Company’s technology has significantly progressed since its original filings and new intellectual property and trade secrets have been developed that will ultimately supersede earlier broad patent applications. Additional patent applications will be filed in due course.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $102 million market valuation Cannabix has $4.9 million in the treasury, and virtually no debt. Cannabix is an exciting story in small caps; Cannabix is the developer of the Patent Pending Cannabis Drug Detection Device for law enforcement and the workplace. As recreational Cannabis is now legal in many US states and will be legal in Canada on October 17 the drug detection space is a booming and fast growing market; according to Market research engine the global Drug Screening Market is Forecast to Cross US$ 8 Billion by 2022. We will be updating on Cannabix when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Cannabix.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Cannabix either long or short and we have not been compensated for this article.